Category: Press Releases

Astrocyte Pharmaceuticals Awarded NIH Small Business Grant to Advance TBI and Concussion Therapeutic

Cambridge, MA, September 21, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a Phase 1 Small Business Technology Transfer (STTR)...

Dr. Susan S. Margulies Joins Astrocyte Pharmaceuticals’ Scientific Advisory Board

Cambridge, MA, July 16, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Susan S. Margulies, Ph.D. has joined the company’s Scientific Advisory Board....

Licensing Agreement Advances Preclinical Therapy for Brain Injuries, Including Concussion

Cambridge, Mass. (May 7, 2015) – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced it has entered into an exclusive worldwide licensing agreement with The University...

Dr. Theodore Liston to Lead Pharmacokinetics and Pharmacodynamics at Astrocyte Pharmaceuticals

Cambridge, Mass., May 1, 2015 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Theodore E. Liston, Ph.D. has joined the company as Vice President of Pharmacokinetics...

Astrocyte’s Dr. James Lechleiter to Present at 2015 TBI Conference

The 5th Annual Traumatic Brain Injury (TBI) Conference is being held on April 15 and 16, 2015 in Washington DC. The conference will feature the latest research findings from many leading TBI researchers...

Former Satori CEO & Pfizer Executive Jeffrey Ives Joins Board of Astrocyte Pharmaceuticals

Cambridge, Mass., December 1, 2014 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Ives, Ph.D. has joined the company’s Board of Directors....

Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders